Booz Allen Commercial delivers advanced cyber defenses to the Fortune 500 and Global 2000. We are technical practitioners and cyber-focused management consultants with unparalleled experience – we know how cyber-attacks happen and how to defend against them.
Our strategy and technology consultants have empowered our international clients with the knowledge and experience they need to build their own local resources and capabilities.
In facing challenges of modernization, our Middle East and North Africa clients have complex requirements that benefit from our proven experience in guiding major programs and projects for governments and private-sector organizations. The services we offer in UAE, Qatar, Egypt, Turkey, Kuwait, Morocco, Jordan, and other regional countries build on our consulting legacy.
Our clients call upon us to work on their hardest problems—delivering effective health care, protecting warfighters and their families, keeping our national infrastructure secure, bringing into focus the traditional boundaries between consumer products and manufacturing as those boundaries blur.
Booz Allen was founded on the notion that we could help companies succeed by bringing them expert, candid advice and an outside perspective on their business. The analysis and perspective generated by that talent can be found in the case studies and thought leadership produced by our people.
Learn more about Booz Allen's diverse culture and environment of inclusion that fosters respect and opportunity for all employees.
We've come a long way delivering innovative solutions. But our next chapter is still being written.
Our 22,600 engineers, scientists, software developers, technologists, and consultants live to solve problems that matter. We’re proud of the diversity throughout our organization, from our most junior ranks to our board of directors and leadership team.
Booz Allen takes pride in a culture that encourages and rewards the many dimensions of leadership—innovative thinking, active collaboration, and personal service. We’re particularly proud of the diversity of our Leadership Team and Board of Directors, among the most diverse in corporate America today.
In a recent panel, Booz Allen joined FDA’s Director of Data Mining and Informatics, HHS Deputy National Coordinator for Health Information Technology, and PNC’s Senior Vice President of Healthcare Product Innovations to discuss how blockchain technologies can improve healthcare quality, cost, and outcomes.
Booz Allen recently hosted a panel of policy leaders and practitioners from both the public and private sector to discuss blockchain’s potential in healthcare.
The panelists all acknowledged that without the advantages offered by blockchain, information availability can only take healthcare so far. Today’s pressing challenge is how to ensure the accuracy, authenticity, and reliability of critical information—at scale.
This discussion at the Capital Health Tech Summit offered insights in three areas that can help leaders put blockchain to work as a potential game changer for healthcare:
Dr. Jon White from the Department of Health and Human Services (HHS) cautioned against seeking a total replacement of the current healthcare economy with any technological advance. Take the shift from faxes and hand-written prescriptions to e-prescribing; the sector achieved significant operational improvement without upheaval and while ensuring that the benefits of this new technology accrued to patients, providers, and payers alike. The goal for blockchain at this early stage is to place bets on small victories that, when they succeed, prove what is in the realm of the possible.
Mary Butler-Everson of PNC explained that blockchain can help eliminate the non-value added activities that burden several stakeholders and even competitors. She gave an example from the banking industry: Major credit card issuers found common cause with the automated clearing house—a critical yet standard function—and adopted shared infrastructure. In healthcare, she advised, the equivalent might be blockchain-based approaches to beneficiary eligibility or patient prior authorizations. Done the way they are today, these two use cases represent non-value added activities to multiple stakeholders.
As with most new technologies, particularly those that impact existing workflows, deploying the technology itself is only part of the challenge. Dr. Henry “Skip” Francis from the Food and Drug Administration (FDA) is currently leading his agency’s blockchain implementation, and raised the importance of easing user adoption to deliver on the promise of blockchain-based solutions.
In addition to anticipating and alleviating concerns that jobs may be replaced or diminished, Dr. Francis emphasized the value of training and enfranchising different user profiles. As part of implementing the FDA’s blockchain solution, he explained how important it was that researchers, doctors, hospital administrators, technologists, and statisticians were considered in the design and implementation of the solution. Ultimately, his agency’s blockchain solution was developed with a spectrum of stakeholders in mind, in a way that achieved alignment and ultimate success.
Dr. White noted that interoperability of health information is a “top national priority.” Indeed, the VA and many private hospital systems have been leading the embrace of the popular FHIR HL7 standard to securely transmit health data. As a result, doctors and hospitals can share electronic health record (EHR) data beyond the boundaries of siloed, centralized databases.
Blockchain technology can take interoperability a step further to improve the exchange of data between healthcare organizations. A team at Booz Allen is working with the FDA to develop a blockchain-based information sharing platform that enables the secure exchange of sensitive data across healthcare settings (We’ll share more about that project below). And what’s more, the integrated use of smart contracts—executable software on a blockchain—gives data owners the power to set selective permissions for better access controls.
Perhaps the most exciting takeaway was the rare discussion of blockchain in practice. Setting aside hypothetical use cases, Dr. Francis discussed his team’s real-world blockchain deployment, which is scaling up throughout this year.
He shared an example of why real-time and secure data sharing became such a critical issue to the agency’s mission of conducting patient outcome surveillance. During the 2009 H1N1 pandemic, the FDA rapidly approved the release of new vaccines to stem the contagion, but monitoring the drug’s effectiveness involved a time-consuming manual process to collect and analyze sensitive patient data contained in thousands of pages of documentation submitted by hospitals to the CDC and the FDA’s Center for Drug Evaluation and Research.
Because of the need to more effectively assess countermeasure drugs during medical events, Dr. Francis explained that the FDA recently implemented a blockchain-based solution with Booz Allen that facilitates real-time exchange of encrypted, permissioned health data between the agency and partner hospitals—generating reliable assessments within 24 hours. And, owing to the unique auditability of blockchains, the solution also enables crucial epidemiological work to determine how and when contagious infections initially spread.
Blockchain technology will continue to change the way we share information in healthcare. As issues continue to rise around data security, accuracy, and access, blockchain applications can help healthcare organizations focus on what matters at the end of the day—the patients—and worry less about single points of failure.